Pharmacokinetic and Clinical Trial Data on Oral vs. Inhaled Losartan for Cystic Fibrosis

A 2026 study by Charles D. Bengtson published on figshare, comprising pharmacokinetic data from sheep and human clinical trials. The dataset, a 373.7 KB PDF, compares airway and serum concentrations of losartan and its metabolites after oral and inhaled administration in the context of cystic fibrosis. It includes results from an open-label clinical trial (NCT03435939) involving seven participants with cystic fibrosis not on CFTR modulators.

Use Cases

• Analyzing airway drug exposure levels based on pharmacokinetic data from sheep models.
• Comparing serum pharmacokinetics of losartan between healthy volunteers and people with cystic fibrosis based on the described study results.
• Evaluating the impact of oral losartan on nasal TGF-β1 levels and systemic inflammatory markers based on clinical trial outcomes.
• Assessing the feasibility of oral versus inhaled drug delivery for achieving therapeutic airway concentrations based on the comparative study.

Strengths

• Includes data from a registered clinical trial (NCT03435939).
• Compares pharmacokinetic results across multiple models: sheep, healthy volunteers, and people with cystic fibrosis.
• Published under a permissive CC-BY-4.0 license for reuse.

Limitations

• The dataset is a single 373.7 KB PDF document; underlying tabular or raw data files are not specified.
• Column-level documentation and sample data are unavailable, requiring manual extraction and interpretation from the PDF.
• The clinical trial component had a small sample size of seven participants, as noted in the description.

Provenance

Source

figshare

Collection Method

Comparative pharmacokinetics studies in sheep and an open-label clinical trial in humans.

Time Range

Study published in 2026; specific data collection dates are not provided.

Freshness

Last updated 2026-05-04 04:18:46.

Geography

Geography is not specified in the provided metadata.